LY-272,015
|
|
| Systematic (IUPAC) name | |
|---|---|
| 1-(3,4-dimethoxybenzyl)-6-methyl-2,3,4,9-tetrahydro-1H-β-carboline | |
| Clinical data | |
| Legal status |
?
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Synonyms | LY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole |
| Chemical data | |
| Formula | C21H24N2O2 |
| Mol. mass | 336.426 g/mol |
|
|
|
|
LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models,[1][2] and is also used in research into the other functions of the 5-HT2B receptor.[3]
References
- ^ Watts SW, Fink GD. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. American Journal of Physiology. 1999 Mar;276(3 Pt 2):H944-52. PMID 10070078
- ^ Russell A, Banes A, Berlin H, Fink GD, Watts SW. 5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat. Journal of Pharmacology and Experimental Therapeutics. 2002 Oct;303(1):179-87. PMID 12235249
- ^ Günther S, Maroteaux L, Schwarzacher SW. Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro. Journal of Neurobiology. 2006 Aug;66(9):949-61. doi:10.1002/neu.20253 PMID 16758492